CoChat

Once‐daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double‐blind, randomized, paroxetine‐controlled, non‐inferiority trial in China, Korea, Taiwan and Brazil

LEE, PHIL, SHU, LIANG, XU, XIUFENG, WANG, CHUAN YUE, LEE, MIN SOO, LIU, CHIA‐YIH, HONG, JIN PYO, RUSCHEL, SANDRA, RASKIN, JOEL, COLMAN, SAMUEL A, HARRISON, GAVAN A · 2007 · Psychiatry and Clinical Neurosciences
Cited by 50

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The aim of the present paper was to compare the efficacy and safety of duloxetine with paroxetine in the acute treatment of major depressive disorder (MDD). In a randomized, double‐blind trial of 8 weeks active treatment, patients with non‐psychotic MDD were randomized to duloxetine 60 mg (n = 238) or paroxetine 20 mg (n = 240) once daily. Efficacy was primarily measured on change in the 17‐item Hamilton Rating Scale for Depression (HAMD 17) using a non‐inferiority test with a margin of 2.2. Secondary efficacy measures included the HAMD 17 subscales, Hamilton Rating Scale for Anxiety, Clinical Global Impressions–Severity, Patient Global Impressions–Improvement, Somatic Symptoms Inventory and Visual Analog Scales (VAS) for pain. Safety measures included treatment‐emergent adverse events (TEAE), vital signs, weight, laboratory analyses and electrocardiograms. Non‐inferiority of duloxetine to paroxetine was demonstrated because the upper bound of the confidence interval for mean difference in HAMD 17 change (0.71) was less than the non‐inferiority margin. Secondary efficacy end‐points did not differ significantly between treatments with the exception of VAS back pain, where the pooled mean was lower in the duloxetine group (17.1) compared with the paroxetine group (20.3, P = 0.048). No significant differences were observed in the number of early discontinuations and overall TEAE. However, significantly greater proportions of patients in the duloxetine group experienced nausea and palpitations. No clinically relevant changes in laboratory values, vital signs, weight or electrocardiograms were observed with either treatment. The present study verifies the utility of duloxetine as an efficacious and safe treatment for both emotional and physical symptoms of MDD in this predominantly Asian patient sample.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1440-1819.2007.01666.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 50

Metadata

Authors
LEE, P., SHU, L., XU, X., WANG, C. Y., LEE, M. S., LIU, C., HONG, J. P., RUSCHEL, S., RASKIN, J., COLMAN, S. A., & HARRISON, G. A.
Venue
Psychiatry and Clinical Neurosciences
Publisher
Wiley
Published
2007-04-28
Volume
61
Issue
3
Pages
295-307
ISSN
  • 1323-1316 (ISSN-L)
  • 1440-1819
OpenAlex
W2098354008
Cited by
50
References
9
FWCI
2.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once‐daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double‐blind, randomized, paroxetine‐controlled, non‐inferiority trial in China, Korea, Taiwan and Brazil. https://app.cochat.ai/papers/10.1111/j.1440-1819.2007.01666.x
The paper
LEE, P., SHU, L., XU, X., WANG, C. Y., LEE, M. S., LIU, C., HONG, J. P., RUSCHEL, S., RASKIN, J., COLMAN, S. A., & HARRISON, G. A. (2007). Once‐daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double‐blind, randomized, paroxetine‐controlled, non‐inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/j.1440-1819.2007.01666.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.